Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11314894 | 0.87 | MAPT (0.47) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL9807415 | 0.84 | ALDH1A1 (0.51) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL14326956 | 0.81 | KMT2A (0.62) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL10138713 | 0.80 | KMT2A (0.51) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL26040453 | 0.80 | KMT2A (0.60) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL6904502 | 0.80 | CYP1A2 (0.60) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL4077298 | 0.80 | CYP1A2 (0.60) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL6904508 | 0.80 | MEN1 (0.66) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL24993893 | 0.80 | ALDH1A1 (0.40) | KMT2AMEN1CYP1A2LMNACYP3A4 | |
| SCHEMBL24994421 | 0.80 | CCR4 (0.41) | KMT2AMEN1CYP1A2LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098466-A1 | Synthesis Of Triphenodioxazine Pigments | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-04-28 | — | — | US | disclosed |
| WO-2009027014-A2 | SYNTHESIS OF TRIPHENODIOXAZINE PIGMENTS | CLARIANT INTERNATIONAL LTD (CH) | 2009-03-05 | — | — | WO | disclosed |
| EP-2031026-A1 | Synthesis of triphenodioxazine pigments | CLARIANT INTERNATIONAL LTD. (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7307170-B2 | Epindolidione pigments | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-12-11 | — | — | US | disclosed |
| US-7307170-B2 | Epindolidione pigments | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-12-11 | — | — | US | disclosed |
| US-7262284-B2 | Method for producing disazo pigments | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| US-20060167236-A1 | Method for producing disazo pigments | CLARIANT GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1201718-B1 | Mixed crystals of benzimidazoloneoxazine derivatives | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2006-05-24 | — | — | EP | disclosed |
| EP-1132432-B1 | Preparation process of pigments | CLARIANT FINANCE BVI LTD (VG) | 2006-02-08 | — | — | EP | disclosed |
| EP-1517962-A1 | METHOD FOR PRODUCING DISAZO PIGMENTS | Clariant GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2002046315-A1 | PROCESS FOR THE PREPARATION OF TRIPHENODIOXAZINE PIGMENTS | CLARIANT FINANCE (BVI) LIMITED (VG) | 2002-06-13 | — | — | WO | disclosed |
| EP-1201718-A2 | Mixed crystals of benzimidazoloneoxazine derivatives | Clariant GmbH (DE) | 2002-05-02 | — | — | EP | disclosed |
| US-6355795-B1 | PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER AND ARE ALSO EASILY DISPERSIBLE | CLARIANT FINANCE (BVI) LIMITED (BV) | 2002-03-12 | — | — | US | disclosed |
| US-20010031864-A1 | Preparation of pigments | CLARIANT FINANCE (BVI) LIMITED | 2001-10-18 | — | — | US | disclosed |
| EP-1132432-A2 | Preparation process of pigments | Clariant Finance (BVI) Limited (VG) | 2001-09-12 | — | — | EP | disclosed |
| EP-1120420-A2 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120421-A2 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 2001-08-01 | — | — | EP | disclosed |
| US-6255482-B1 | PREPARING CHLORINE-CONTAINING TRIPHENDIOXAZINE COMPOUNDS USEFUL AS PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION, AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-07-03 | — | — | US | disclosed |
| EP-0911337-A1 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 1999-04-28 | — | — | EP | disclosed |
| US-3956266-A | DISAZO DYES | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098466-A1 | Synthesis Of Triphenodioxazine Pigments | TYR, SCO2, NDUFS5 | KMT2A 3089/4885MEN1 3867/4885CYP1A2 104/4885 |
| US-20060167236-A1 | Method for producing disazo pigments | TYR, IPO4, CBR3 | KMT2A 2138/4885MEN1 2054/4885CYP1A2 40/4885 |
| US-20010031864-A1 | Preparation of pigments | SCO2, PPOX, PRDX4 | KMT2A 1664/4885MEN1 216/4885CYP1A2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.